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Background/aim: The aim of this study was to reveal the tetanus immunization status of diabetic patients and to determine whether
diabetic patients with foot ulcers have different TIG levels.
Materials and methods: A cross-sectional study was designed that included diabetic patients with foot ulcers (n = 30) and diabetic
patients without ulcers (n = 30). The groups were compared for serum TIG levels along with total serum protein, albumin, C-reactive
protein (CRP), and total immunoglobulin G (Ig G).
Results: For diabetic patients without foot ulcers, 17 of 30 (56.6%) patients were found to have nonprotective TIG levels whereas for
diabetic patients with foot ulcers, 28 of 30 (93.3%) patients were found to have nonprotective TIG levels. The mean value of TIG for
diabetic patients without foot ulcers was 0.345 ± 0.281 IU/mL and for diabetic patients with foot ulcers the mean TIG value was 0.055
± 0.033 IU/mL. Statistically significant differences were observed in TIG (P = 0.008), total protein (P < 0.001), albumin (P < 0.001), and
CRP levels (P < 0.001) between the two groups.
Conclusion: The majority of the diabetic patients had low TIG levels and they were significantly lower in diabetic patients with ulcers.
A booster dose of tetanus vaccine should be considered for diabetic patients with and without diabetic foot ulcers.
Key words: Diabetes mellitus, diabetic foot ulcer, tetanus immunoglobulin

1. Introduction
Clostridium tetani is a drumstick-shaped gram-positive
anaerobic bacterium that is abundantly found as spores in
soil, human skin, and the gastrointestinal tract. It is known
to synthesize two potent biological toxins: tetanolysin and
tetanospasmin (1). Tetanolysin is responsible for tissue
destruction observed during the course of infection.
Tetanospasmin is a neurotoxin responsible for tetanus,
which is characterized by painful muscular spasms,
leading to respiratory failure and associated with a very
high mortality rate. Tetanospasmin is known to act by
interfering with the release of inhibitory neurotransmitters
(glycine and gamma-aminobutyric acid), thereby
increasing resting motor neuron activity, leading to
muscular rigidity and spasms (2,3).
* Correspondence: drfatihtekin@hotmail.com
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C. tetani cannot survive in the presence of oxygen
during its growth, which makes necrotic and vascularly
compromised tissue a suitable host for proliferation of this
bacterium.
Diabetes mellitus (DM) is a chronic systemic disease
characterized by impaired wound healing and increased
tendency for the patients to develop infections as a result
of immune dysfunctions.
Although there has been an overall decrease in the total
number of cases of tetanus and its morbidity as a result of
effective vaccination programs, it is still a matter of major
concern with an annual incidence of 0.1 per one million
population overall and 0.23 per million among people
aged ≥65 years in United States with almost one million
mortalities worldwide annually (4,5).
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Tetanus is particularly more common in patients with
chronic wounds. There are increasing numbers of studies
that show a decrease in tetanus immunoglobulin (TIG)
levels with age and with the presence of chronic ulcers
(6,7).
Contaminated wounds and chronic leg ulcers are
generally the main portals of entry of C. tetani spores
and therefore regarded as the main etiologic factors in
the pathogenesis of tetanus. Diabetic patients are prone
to develop chronic leg/foot wounds that can easily
be complicated with tetanus. Therefore, vaccination
and immunization status are important parameters
in assessing the risk of tetanus and preventing tetanus
infections. Although there are studies about the tetanus
immunization status of patients with DM or chronic leg
ulcers of any cause, there is no comparison of TIG levels
between diabetic patients with and without leg ulcers.
The findings of our study may, in turn, affect the tetanus
vaccination protocols for these patients.
In the present study we measured and compared TIG
levels among patients with diabetes mellitus type 2 who
have leg ulcers and who do not, and thereby to determine
the vaccination needs of the two different groups.
2. Materials and methods
The study was approved by Keçiören Training and
Research Hospital Regional Ethics Committee (Decision
Number: 22.02.2012 /B.10.4.İSM.4.06.68.49/09). A crosssectional study was designed and total protein, albumin,
C-reactive protein (CRP), hemoglobin A1c (HbA1c), total
immunoglobulin G (IgG), and TIG levels of 60 diabetic
patients were assessed. Only patients without a vaccination
history in the previous 5 years were included in this study.
Two groups were formed, each of which contained 30
patients. Group 1 was defined as patients with DM but
without diabetic foot ulcers. Group 2 was defined as
patients with DM accompanied by diabetic foot ulcers
with Wagner class 2 and 3. For group 2, patients with a
chronic wound history of more than 3 months and more

than 2 cm diameter without acute purulent discharge were
selected for the study. The diabetic patients with ischemic
or venous lower extremity wounds, smoking history, and
systemic complications (chronic renal failure, congestive
heart failure, etc.) were excluded from the study. The
inclusion criteria for the study are summarized in Table 1.
Serum levels of total protein, albumin, CRP, HbA1c,
total IgG, and TIG levels were compared between the two
groups. The parametric variables were compared using the
independent sample t-test and nonparametric variables
were compared using the Mann–Whitney U test. The
comparison of frequencies among the two groups was
analyzed using the chi-squared test. Statistical significance
was determined as P < 0.05 with a confidence interval of
95%.
3. Results
In group 1, there were 13 male and 17 female patients and
in group 2 there were 24 male and 6 female patients (Table
2). The mean age in group 1 was 60.5 ± 13.9 years and in
group 2 it was 56.2 ± 9.5 years. The mean duration of DM
was 7.7 ± 4.3 years in group 1 and 8.5 ± 6.1 years in group
2. There was no statistically significant difference in terms
of age or duration of diabetes between the groups (Table
2). The mean wound diameter was 3.9 ± 0.9 cm and mean
wound duration was 7.3 ± 3.7 (range: 3–15) months.
The normal laboratory values for the parameters used
in the study were based on our laboratory’s reference
values and are listed in Table 3.
Diabetic patients with and without foot ulcers were
compared in terms of their serum TIG, total protein,
albumin, CRP, total IgG, and HbA1c levels.
Mean serum total protein, albumin, CRP and
HbA1c, total IgG, TIG levels and standard deviations are
summarized in Table 3 and graphically presented in the
Figure.
TIG levels were significantly lower in diabetic patients
with foot ulcers (0.055 ± 0.033 IU/mL) when compared
to patients without foot ulcers (0.345 ± 0.281 IU/mL) (P

Table 1. Inclusion criteria for the study.
No finding of ischemia or venous insufficiency of the extremity
No finding of acute cellulitis, no acute purulent discharge
At least 3-month duration of lower extremity wound
Wound diameter > 2 cm
No tetanus vaccination history in the previous 5 years
No other systemic disease complicating diabetes (chronic renal failure, congestive heart failure, vasculitis, immune disorder)
No smoking history
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Table 2. Age, sex, mean duration of diabetes, and mean wound diameter data collected in the
study.
Group 1
(mean ± SD*)

Group 2
(mean ± SD*)

60.5 ± 13.9

56.2 ± 9.5

Male

13

24

Female

17

6

Mean duration of DM (years)

7.7 ± 4.3

8.5 ± 6.1

Mean duration of wound (months)

No wound

7.3 ± 3.7

Mean wound diameter (centimeters)

No wound

3.9 ± 0.9

Age (years)

Sex

*SD: Standard deviation
Group 1 = DM patients without ulcers; Group 2 = DM patients with ulcers
Table 3. Mean and standard deviation values of the laboratory tests in our study.
Group 1
(mean ± SD)

Group 2
(mean ± SD)

Reference valuesc

Total protein

7.50 ± 0.30 g/dL

6.48 ± 0.41 g/dL

6–8 g/dL

Albumin

4.23 ± 0.18 g/dL

2.82 ± 0.55 g/dL

3.5–5.5 g/dL

CRP

0.37 ± 0.19 mg/dL

9.17 ± 8.1 mg/dL

<0.5 mg/dL

HbA1c

70.5 ± 4.9 mmol/mol IFCCa
(8.6 ± 2.6% DCCTb)

83.6 ± 6.0 mmol/mol IFCCa
(9.8 ± 2.7% DCCTb)

<48 mmol/mol IFCCa
(<6.5% DCCTb)

Total IgG

1330 ± 189 mg/dL

1428 ± 369 mg/dL

640–1430 mg/dL

Tetanus IgG

0.345 ± 0.281 IU/mL

0.055 ± 0.033 IU/mL

>0.15 IU/mL*

The International Federation of Clinical Chemistry and Laboratory Medicine
The Diabetes Control and Complications Trial (DCCT)
c
Normal laboratory values for the tests used in the study according to our laboratory’s reference values
* >0.15 IU/mL is regarded as protective
a

b

= 0.008). When the laboratory reference value of TIG
is accepted as the cut-off point to classify patients as
protected and nonprotected, it is clearly demonstrated that
17 of the 30 patients (56.6%) among the diabetic patients
without foot ulcers had nonprotective TIG levels, whereas
28 of the 30 patients (93.3%) among the diabetic patients
with ulcers had nonprotective TIG levels (Table 4).
Moreover, 45 of the 60 patients (75%) overall and 13 of
the 15 (86.6%) patients over the age of 70 had TIG values
below protective levels.
Total protein and albumin were significantly lower
and CRP levels were significantly higher in the diabetic
patients with foot ulcers (P < 0.001).
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4. Discussion
The incidence of tetanus is 0.1 per million of the population.
Twelve percent of all tetanus patients have diabetes.
Diabetes is clearly associated with an increased risk of
tetanus, especially in the elderly, with tetanus incidence
reaching up to 0.70 cases per million for diabetic patients
over the age of 60. According to Centers for Disease
Control and Prevention (CDC) data, diabetic foot ulcers
and gangrene are a major route for tetanus infections.
Chronic wounds, which are more commonly observed in
diabetic patients, were shown to be the etiologic factor in
about 26% of tetanus cases (4,8,9).
Diabetic patients are more prone to C. tetani infections
because of several risk factors associated with diabetes. The
microvascular angiopathy in diabetic patients together with
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Figure. Comparison of laboratory values between the groups with chart graphs and standard deviation bars.
Table 4. Tetanus IgG levels among the groups.
Tetanus IgG levels

Group

Nonprotective

Protective

Total

Diabetics without ulcers

17

13

30

Diabetics with ulcers

28

2

30

Total

45

15

60

increased atherosclerosis affecting macrovasculature leads
to decreased tissue perfusion and oxygen partial pressure.
This vascular insufficiency together with infection causes
tissue necrosis, which is called gangrene. This creates a

culture medium for the growth of C. tetani (10). Tetanus
spores need to penetrate the skin and proliferate only in
anaerobic conditions. Almost 15% of diabetic patients
have been shown to develop diabetic foot ulcers during
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their lifespan (11). The decreased perfusion also limits the
total number of immune cells delivered to the infection
site (12).
Diabetes has been shown to impair cellular
and humoral immunity, which is characterized by
abnormalities in antibody titers associated with possible
B-cell dysfunction and impairments in margination,
chemotaxis, phagocytosis, and bactericidal functions,
which are vital in immune defense (13–18).
In various studies about TIG levels comparing diabetic
and nondiabetic patients, it has been reported that type
2 DM is associated with decreased TIG levels in patients
who have previously been immunized (6,7,19,20).
In our study, when the two groups (DM patients with
and without diabetic foot ulcers) were compared in terms
of TIG values, diabetic patients with ulcers were found
to have significantly lower TIG levels when compared
to patients without ulcers. Although the underlying
mechanisms have not yet been fully enlightened, diabetic
immunopathy, chronic inflammation, continuous exposure
to the relevant bacteria, and antibody consumption are
the suggested pathophysiological mechanisms that might
cause decreased TIG levels.
One of the limitations in our study was the lack of
a healthy control group for comparison of TIG levels.
The healthy control group was excluded because of the
significantly lower mean age of this group, which made the
statistical comparison unmeaningful.
Poorly controlled blood glucose levels are strongly
associated with diabetic peripheral neuropathy, diabetic
immune dysfunction, and poor wound healing, all of
which eventually cause foot ulcers in diabetic patients. In
our study there was no significant difference in HbA1c
levels between the groups and there was no correlation
between HbA1c and TIG levels.
In the current literature, increased age seems to
correlate with decreased serum IgG levels (21,22). Cook
et al. reported that 49%–66% of people over the age of 60
have TIG levels below the protective range (23). Nemati
et al. reported that TIG levels were significantly lower in
patients over 40 years old in their younger patient series

(7). Tamer et al. reported that TIG levels were decreased
in diabetic patients older than 50 years of age, whereas this
decrease was seen at the age of 65 in healthy individuals
(20).
In our study there was no correlation between increased
age and TIG levels, possibly because of the relatively narrow
age range of patients, making it difficult to demonstrate a
clear correlation between increased age and decreased TIG
levels. The patients included in our study were already at
older ages and yet 45 of the 60 patients (75%) had TIG
levels below the protective range.
Although humoral immunity is known to be affected
by uncontrolled DM, there are studies with different
findings regarding immunization response to vaccines.
Type 2 diabetic patients have been reported to have
decreased vaccine responses to hepatitis B virus (24) and
influenza A virus (25); however, they have been reported
to have almost normal vaccination responses to tetanus
toxoid vaccine (26).
Tetanus vaccination with a booster dose is already in
use for diabetic patients with acute foot infections with
purulent discharge. In our study it is clear that the majority
of the diabetic foot patients attending our clinics have not
received proper tetanus prophylaxis probably because of
the chronic and insidious course of these ulcers. Those
patients with no sign of acute infection are often neglected
for tetanus prophylaxis. Therefore, a tetanus booster
should be administered to all patients with diabetic foot
ulcers even though they do not manifest signs of acute
infection, osteomyelitis, or partial foot necrosis.
In conclusion, the majority of patients with chronic
wounds are known to be vulnerable to tetanus infections.
Yet the major protective mechanism against C. tetani
infections is tetanus IgG. Diabetic patients with foot
ulcers have lower TIG values. The majority of diabetic foot
patients do not receive proper tetanus prophylaxis since
these patients are usually neglected because of the lack of
signs of acute infection. Hence, a tetanus booster should
be administered to all diabetics regardless of presence or
status (acute vs. chronic) of foot ulcers.
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